Bradley J Monk

43PUBLICATIONS
253CO-AUTHORS
Molecular targetsPredictive and prognostic markersOncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Discourse and pragmatics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (43)

|Jan 14, 2026
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer.

Robert L Coleman, Rodney Rocconi, Bradley J Monk

|Oct 31, 2025
Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer.

Bradley J Monk, Robert L Coleman, David M O'Malley

|Jul 23, 2025
Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation.

Panagiotis A Konstantinopoulos, Jae Weon Kim, Gilles Freyer

|Jul 11, 2025
Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.

Susana N Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian

|Jul 01, 2025
Pembrolizumab plus chemotherapy with or without bevacizumab in East Asian participants with persistent, recurrent, or metastatic cervical cancer: results from KEYNOTE-826 final analysis.

Yong-Man Kim, Shin Nishio, Se Ik Kim

|Dec 05, 2024
Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.

Hailei Zhang, Anna Rutkowska, Antonio González-Martín

Pageof 8

Frequent Collaborators

9 joint publications

David M O'Malley

9 joint publications

Mansoor Raza Mirza

8 joint publications

Domenica Lorusso

8 joint publications

Robert L Coleman